SNUBH Clinical Pharmacololgy and Therapeutics

Medicine & Life Sciences

1. Pharmacokinetics 100%
2. Healthy Volunteers 53%
3. Metformin 28%
4. Genotype 20%
5. Therapeutic Equivalency 19%
6. Pharmaceutical Preparations 17%
7. Safety 15%
8. Area Under Curve 15%
9. Tablets 12%
10. Placebos 12%
11. Oral Administration 11%
12. Genetic Polymorphisms 11%
13. Atorvastatin 9%
14. Vancomycin 9%
15. Cytochrome P-450 CYP3A 9%
16. delpazolid 9%
17. Alleles 8%
18. Cytochrome P-450 CYP2B6 8%
19. Cross-Over Studies 8%
20. Population 8%
21. Single Nucleotide Polymorphism 8%
22. olmesartan 7%
23. Moxifloxacin 7%
24. Elderly 7%
25. Cytochrome P-450 CYP2C19 7%
26. Proton Pump Inhibitors 6%
27. Ursodeoxycholic Acid 6%
28. Pregnane X Receptor 6%
29. Rabbits 6%
30. pitavastatin 6%
31. Citalopram 6%
32. Haplotypes 6%
33. Oxazolidinones 6%
34. Volunteers 6%
35. Half-Life 6%
36. Urine 5%
37. Biological Availability 5%
38. aflibercept 5%
39. Rifampin 5%
40. Lorazepam 5%
41. Glucose 5%
42. Hypoglycemic Agents 5%
43. 2-hydroxyatorvastatin 5%
44. Amlodipine 5%
45. 3-(3-ethyl-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carbonyl)-5-methylbenzonitrile 5%
46. Clinical Studies 5%
47. Eye 5%